99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis

dc.authoridCermik, Tevfik Fikret/0000-0001-7622-7277
dc.authoridKarlikaya, Celal/0000-0001-7084-4987
dc.authorwosidCermik, Tevfik Fikret/A-9694-2018
dc.authorwosidKarlikaya, Celal/JMR-3834-2023
dc.contributor.authorYüksel, M
dc.contributor.authorÇermik, TF
dc.contributor.authorDoganay, L
dc.contributor.authorKarlikaya, C
dc.contributor.authorÇakir, E
dc.contributor.authorSalan, A
dc.contributor.authorBerkarda, S
dc.date.accessioned2024-06-12T11:09:20Z
dc.date.available2024-06-12T11:09:20Z
dc.date.issued2002
dc.departmentTrakya Üniversitesien_US
dc.description.abstractHigher technetium-99m methoxyisobutylisonitrile (MIBI) uptake in non-small cell lung cancer (NSCLC) has been reported to be associated with a positive response to chemotherapy. It has previously been found that in tumour cells, P-glycoprotein (Pgp) expression is of importance for tracer uptake. However, some studies have indicated that Pgp expression does not play an important role in Tc-99m-MIBI uptake in NSCLC; indeed, a negative correlation between 99mTc-MIBI uptake and Pgp expression has been reported. Against the background of conflicting results, our aim was to evaluate the relationship between Tc-99m-MIBI uptake, prognosis and Pgp expression in NSCLC. A total of 37 patients with NSCLC underwent Tc-99m-MIBI single-photon emission tomography (SPET) before chemotherapy. In 19 patients both Pgp and p53 expression, and in two patients only p53 expression (due to the limited biopsy material), were measured with immunohistochemical staining. Tc-99m-MIBI uptake was significantly higher in responders than in non-responders: 3.09+/-1.14 vs 2.24+/-0.88 (P<0.03) and 3.09+/-1.08 vs 2.37+/-1.06 (P<0.05) for the early ratio (ER) and the delayed ratio (DR), respectively. The wash-out rate (WR) of responders was not significantly different from that of non-responders. We found no significant differences in ER, DR and WR among the groups positive or negative for Pgp and p53 status. There was a significant positive correlation between the survival rate and both ER and DR: r=0.49 (P=0.003) and r=0.40 (P=0.018), respectively. Patients with ER and DR values above 3 showed significantly longer survival than those with values below 3: 14.7+/-8.5 months vs 7.3+/-5.1 months (P<0.009) and 13.2+/-8.4 months vs 7.4+/-5.3 months (P<0.04) for ER and DR, respectively. However, interestingly, and in contrast to expectations, patients with a Pgp score of +2 showed significantly longer survival (12.9+/-6.7 months) than those with Pgp scores of +1 (4.4+/-3.0 months) or - (negative) (3.8+/-2.2 months) (P<0.009 and P<0.02, respectively). Our results suggest that in NSCLC, patients with higher Tc-99m-MIBI uptake tend to show a positive response to chemotherapy, and patients with ER and DR values above 3 have a significantly better prognosis. We also found that Pgp expression seems to play only a minor role in Tc-99m-MIBI uptake. Our finding that patients with ER and DR values above 3 have a better prognosis needs to be confirmed in larger series of patient.en_US
dc.identifier.doi10.1007/s00259-002-0804-7
dc.identifier.endpage881en_US
dc.identifier.issn1619-7070
dc.identifier.issn1619-7089
dc.identifier.issue7en_US
dc.identifier.pmid12111127en_US
dc.identifier.scopus2-s2.0-0036089942en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage876en_US
dc.identifier.urihttps://doi.org/10.1007/s00259-002-0804-7
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22775
dc.identifier.volume29en_US
dc.identifier.wosWOS:000177001600006en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofEuropean Journal Of Nuclear Medicine And Molecular Imagingen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNon-Small Cell Lung Canceren_US
dc.subjectTc-99m-MIBI P-Glycoproteinen_US
dc.subjectP53en_US
dc.subjectChemotherapyen_US
dc.subjectP-Glycoprotein Expressionen_US
dc.subjectChemotherapeutic Responseen_US
dc.subjectP53en_US
dc.subjectMibien_US
dc.subjectAccumulationen_US
dc.subjectGlutathioneen_US
dc.subjectIsonitrileen_US
dc.subjectSurvivalen_US
dc.subjectGrowthen_US
dc.subjectGeneen_US
dc.title99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosisen_US
dc.typeArticleen_US

Dosyalar